Core Insights - Biomerica, Inc. has received authorization from the Egyptian Drug Authority for its complete portfolio of rapid diagnostic tests, enhancing access to early detection tools for cancer and chronic diseases in Egypt [1][2][10] Product Portfolio - The authorized screening tests include those for colorectal disease, breast self-examination, prostate disease, kidney disease, and H. pylori infection, all designed for point-of-care use [1][3][7] - Tests provide quick results within minutes and do not require laboratory sample processing, making them suitable for diverse clinical and community settings [3][14] Market Need - Colorectal cancer is the 7th most common cancer in Egypt, with an incidence of approximately 5 to 10 cases per 100,000 persons per year, and a concerning trend of late-stage diagnoses [4] - Breast cancer is the most common cancer among women in Egypt, with an age-standardized incidence rate of about 55.4 per 100,000 persons per year, and poorer mortality outcomes due to late-stage diagnosis [5] - Prostate cancer ranks as the fourth most common cancer in Egypt, with increasing incidence rates [6] Health Statistics - Approximately 13% of adults in Egypt are living with chronic kidney disease, which has been among the top five causes of death from 2009 to 2019 [8] - H. pylori infection prevalence in Egypt ranges from 50% to 70%, affecting a significant portion of the population [8] Strategic Impact - The authorization supports national public health efforts to improve early disease detection, enhance health outcomes, and reduce long-term healthcare costs [9][10] - Biomerica's expansion in the Middle East and North Africa (MENA) region is reinforced by this authorization, aligning with global preventive care trends [11]

Core Insights - XBP Global Holdings, Inc. has entered into a five-year agreement with BG-Phoenics GmbH, valued at up to 21.5 million Euro, to provide workflow automation services in Germany's statutory accident insurance sector [1][2][4] Group 1: Agreement Details - The contract involves XBP Global transitioning the client's mail processing from paper-based workflows to AI-driven digital document management [2][4] - XBP Global will utilize its Intelligent Document Processing (IDP) Software platform to process and digitize up to 148 million pages during the contract period [3][4] Group 2: Strategic Positioning - This agreement enhances XBP Global's presence in the German public sector and reinforces its reputation as a strategic partner for technology-enabled document management services [2][4] - The engagement follows a competitive tender process and aligns with XBP Global's strategy to strengthen its foothold in regulated industries and key European markets [4] Group 3: Company Overview - XBP Global operates in 20 countries with approximately 11,000 professionals and partners with over 2,500 clients, including many Fortune 100 companies [6][7] - The company focuses on intelligent workflows and hyper-automation, leveraging its proprietary platforms and AI-driven automation to support digital transformations [7]

Core Insights - Cadrenal Therapeutics has acquired VLX-1005 and related 12-LOX assets from Veralox Therapeutics, enhancing its pipeline with a late-stage drug candidate aimed at the $40 billion global anticoagulation market [1][4] Company Overview - Cadrenal Therapeutics is focused on developing innovative therapeutics to address gaps in anticoagulation management for high-risk patient populations, with three clinical-stage assets including VLX-1005, tecarfarin, and frunexian [6] Product Details - VLX-1005 is a selective small-molecule inhibitor of 12-LOX, targeting immune platelet-mediated inflammation and addressing heparin-induced thrombocytopenia (HIT), which affects up to 5% of patients exposed to heparin [2][8] - The drug has received Orphan Drug Designation and Fast Track designation from the FDA, indicating its potential significance in treating rare conditions [4][8] Clinical Development - Phase 1 studies of VLX-1005 showed it was well tolerated with no serious adverse events, while a Phase 2 study indicated promising reductions in thromboembolic events among patients with suspected HIT [3][4] - The market for HIT treatment is estimated to reach $1 billion in the US and EU, highlighting the commercial potential of VLX-1005 [5] Acquisition Terms - The acquisition agreement includes upfront and milestone payments to Veralox contingent on future clinical and regulatory achievements, as well as royalties on global sales of VLX-1005 [5]

Dubai and Dhaka, December 11, 2025 - VEON Ltd. (Nasdaq: VEON), a global digital operator (“VEON”), today announces that Banglalink, its digital operator in Bangladesh, has received the permission of Bangladesh Bank to operate as a payment service provider - a milestone in the operator’s ambition to expand further into digital financial services. As a payment services provider, Banglalink will be able to offer regulated money transfer and payment services for customers, expanding access to formal financial ...

HOUSTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Par Pacific Holdings, Inc. (NYSE and NYSE Texas: PARR) (“Par Pacific”) today announced it has repriced and allocated its existing term loan credit agreement due 2030 (the “Term Loan Facility”). The repricing amendment, which is expected to close on or about December 17, 2025 subject to customary closing conditions, will reduce the Applicable Margin under the Term Loan Facility by fifty (50) basis points, such that Base Rate loans and SOFR loans will bear interest a ...

CHICAGO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- A recent round of open-market purchases marks another display of confidence as the small molecule telomere-targeting cancer therapy by MAIA Biotechnology, Inc. (NYSE American: MAIA) advances through mid- to late-stage clinical development. Newly filed disclosures show that CEO Dr. Vlad Vitoc and other board members acquired approximately 182,445 shares between November 21 and 28, 2025. Insiders’ participation has been viewed by the market as a strong signal of alig ...

Portage, Michigan, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.88 per share payable January 30, 2026, to shareholders of record at the close of business on December 31, 2025, representing an increase of 4.8% versus the prior year and previous quarter. “We remain confident in our ability to deliver strong financial performance, and consistent with our capital allocation priorities we are increasing our dividend to $0.88 p ...

ORLANDO, Fla., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Innventure, Inc. (NASDAQ: INV) today announced that it has been added to the Russell 2000® Index and the broader Russell 3000® Index, effective at the open of U.S. equity markets on December 22, 2025, as part of the annual Russell indexes reconstitution. In addition, Innventure has been included in the Russell Microcap® Index, which measures the performance of the microcap segment of the U.S. equity market. "Being added to the Russell indexes is an important ...

NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- As part of its ongoing corporate transformation, Society Pass Inc. (Nasdaq: SOPA) (the “Company”), Southeast Asia’s (SEA) next generation e-commerce ecosystem, today announces the evolution of its business model to re-position itself as an acquirer and operator of AI-driven software and network infrastructure companies located in SEA, Europe and North America. The Company looks to invest in and acquire equity stakes in data centre and telecoms operators over the n ...

Core Insights - Vera Bradley, Inc. reported third quarter revenues of $62.3 million, a decrease from $70.5 million in the same period last year, indicating ongoing challenges in the market [4][5] - The company is implementing a transformation strategy called Project Sunshine, focusing on brand optimization and operational excellence [2][3] - Despite a net loss of $12.4 million for the third quarter, the company noted improvements in direct segment sales and a positive response to the return of iconic product styles [3][4] Financial Performance Summary - **Third Quarter Results**: Consolidated net revenues were $62.3 million, down from $70.5 million year-over-year. The net loss from continuing operations was $12.4 million, or $0.44 per diluted share, impacted by a $5.9 million inventory write-down and a $4 million media credit write-off [4][6] - **Nine Month Results**: For the nine months ended November 1, 2025, net revenues totaled $184.8 million, down from $232.4 million in the prior year. The net loss from continuing operations was $35.3 million, or $1.26 per diluted share [5][6] Segment Performance - **Direct Segment**: Revenues decreased by 5.3% to $49.7 million compared to $52.5 million in the prior year. Comparable sales declined by 5.8%, primarily due to reduced traffic in outlet channels [8][10] - **Indirect Segment**: Revenues fell by 30.2% to $12.6 million from $18.0 million in the previous year, attributed to a decline in specialty and key account orders [9][15] Gross Profit and Expenses - **Gross Profit**: Totaled $26.2 million, representing 42.1% of net revenues, down from 54.5% in the prior year, primarily due to inventory write-downs and increased duty expenses [10][16] - **SG&A Expenses**: Totaled $38.7 million, or 62.1% of net revenues, compared to 66.3% in the prior year, reflecting cost reduction initiatives [11][17] Operating Loss - The operating loss from continuing operations for the third quarter was $12.2 million, or 19.6% of net revenues, compared to a loss of $8.2 million, or 11.6% of net revenues, in the prior year [12][18] Balance Sheet Highlights - Cash and cash equivalents as of November 1, 2025, were $10.7 million, down from $12.3 million at the end of the previous year's third quarter. Total inventory decreased to $82.9 million from $109.6 million [20][21] Strategic Initiatives - Project Sunshine aims to enhance brand focus, improve digital capabilities, and optimize operational processes, with early signs of success noted in sales performance [2][3]